Tuberculosis, Human Immunodeficiency Virus, and the Association With Transient Hyperglycemia in Periurban South Africa by Kubjane, Mmamapudi et al.
M A J O R  A R T I C L E
TB/HIV and Hyperglycemia in South Africa • cid 2019:XX (XX XXXX) • 1
Clinical Infectious Diseases
 
Received 31 May 2019; editorial decision 10 September 2019; accepted 16 September 2019; 
published online September 26, 2019.
Correspondence: T. Oni, Faculty of Health Sciences, University of Cape Town, Anzio Road, 
Observatory, Cape Town 7925, South Africa (tolullah.oni@mrc-epid.cam.ac.uk).
Clinical Infectious Diseases®  2019;XX(XX):1–9
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society 
of America. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/cid/ciz928
Tuberculosis, Human Immunodeficiency Virus, and the 
Association With Transient Hyperglycemia in Periurban 
South Africa
Mmamapudi Kubjane,1 Natacha Berkowitz,1,2 Rene Goliath,2 Naomi S. Levitt,3 Robert J. Wilkinson,2,4,5 and Tolu Oni1,2,6
1Division of Public Health Medicine, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa; 2Wellcome Centre for Infectious Disease Research in Africa, 
Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, Observatory, South Africa; 3Division of Diabetes and Endocrinology, Department 
of Medicine, Groote Schuur Hospital, Cape Town, South Africa and Chronic Disease Initiative for Africa; 4The Francis Crick Institute, London, United Kingdom; 5Department of Infectious Diseases, 
Imperial College London, United Kingdom; and 6Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge CB2 0QQ, United Kingdom
Background. Diabetes mellitus (DM) increases tuberculosis (TB) risk. We assessed the prevalence of hyperglycemia (DM 
and impaired glucose regulation [IGR]) in persons with TB and the association between hyperglycemia and TB at enrollment and 
3 months after TB treatment in the context of human immunodeficiency virus (HIV) infection.
Methods. Adults presenting at a Cape Town TB clinic were enrolled. TB cases were defined by South African guidelines, while 
non-TB participants were those who presented with respiratory symptoms, negative TB tests, and resolution of symptoms 3 months 
later without TB treatment. HIV status was ascertained through medical records or HIV testing. All participants were screened for 
DM using glycated hemoglobin and fasting plasma glucose at TB treatment and after 3 months. The association between TB and 
DM was assessed.
Results. Overall DM prevalence was 11.9% (95% confidence interval [CI], 9.1%–15.4%) at enrollment and 9.3% (95% CI, 6.4%–
13%) at follow-up; IGR prevalence was 46.9% (95% CI, 42.2%–51.8%) and 21.5% (95% CI, 16.9%–26.3%) at enrollment and fol-
low-up. TB/DM association was significant at enrollment (odds ratio [OR], 2.41 [95% CI, 1.3–4.3]) and follow-up (OR, 3.3 [95% 
CI, 1.5–7.3]), whereas TB/IGR association was only positive at enrollment (OR, 2.3 [95% CI, 1.6–3.3]). The TB/DM association was 
significant at enrollment in both new and preexisting DM, but only persisted at follow-up in preexisting DM in patients with HIV-1 
infection.
Conclusions. Our study demonstrated high prevalence of transient hyperglycemia and a significant TB/DM and TB/IGR associ-
ation at enrollment in newly diagnosed DM, but persistent hyperglycemia and TB/DM association in patients with HIV-1 infection 
and preexisting DM, despite TB therapy.
Keywords.  tuberculosis; HIV; diabetes; infectious disease; NCD; multimorbidity.
Mortality in South Africa is characterized by concurrent in-
fectious and noncommunicable diseases. The 2015 mortality 
report confirms this transition, with tuberculosis (TB) and dia-
betes mellitus (DM) ranked the first and second leading causes 
of death, while human immunodeficiency virus type 1 (HIV-
1) was ranked fifth [1]. Although the role that HIV-1 plays as 
a significant driver of the TB epidemic is well recognized, the 
emerging and rapidly growing burden of DM, another TB risk 
factor, presents another challenge to TB control.
An increasing body of research shows an association between 
DM and TB [2, 3]. This association is becoming more apparent 
due to the epidemiological transition as DM is growing rapidly 
in settings where HIV-1 and TB epidemics persist. Diabetes in-
creases the risk of developing TB and is also associated with 
adverse treatment outcomes, including death [3–6].
Tuberculosis increases insulin resistance and stress-induced 
hyperglycemia that may revert to normal during treatment [7, 
8]. Therefore, testing for DM in persons with recently diagnosed 
TB may lead to misclassification of transient hyperglycemia as 
DM, and overestimation of the diabetes/TB association. Testing 
for DM in TB patients is recommended, with confirmatory tests 
after 2–3 months of TB treatment initiation [9, 10]; however, the 
optimal time for screening and implications for clinical man-
agement are unknown.
The interplay between TB and DM in the context of HIV-1 
infection remains unclear due to limited data particularly in the 
African context. A recent review that only included 3 African 
studies reported odd ratios (ORs) of TB in DM patients ranging 
from 0.9 (95% confidence interval [CI], .2–4.6) to 10.7 (95% CI, 
4.5–26.0) [11]. A previous study in Cape Town demonstrated 
significant TB and DM association in the group with HIV 
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infection (OR, 2.4 [95% CI, 1.1–5.2]) vs HIV-uninfected pa-
tients (OR, 2.4 [95% CI, .9–6.7]) [12]. A study in Tanzania ob-
served a stronger TB/DM association among people living with 
HIV [13], while another Tanzanian study observed stronger 
TB/DM association in HIV-1–uninfected persons (OR, 4.2 
[95% CI, 1.5–11.6]) compared with people living with HIV 
(OR, 0.1 [95% CI, .01–1.8]) [14]. These 3 diseases interact, with 
the potential to influence risk of disease and prognosis and to 
complicate clinical management [15].
The objective of this study was to assess the association 
between hyperglycemia and TB, at TB diagnosis, and after 
3 months of TB treatment.
METHODS
Study Setting and Population
This study was conducted at the largest public-sector TB clinic 
in Khayelitsha, a periurban township of approximately 390  000 
predominantly black Africans, in Cape Town, Western Cape 
province, where DM, HIV-1, and TB rank as the first, third, and 
fifth leading causes of death, respectively [1]. The 2012 HIV-1 
antenatal prevalence in Khayelitsha was 34% (95% CI, 31.0%–
36.6%) (Western Cape Department of Health, Cape Town, 
South Africa; 2012 Antenatal Survey, unpublished data) and 
the 2015 TB case notification rate was 917 per 100  000 popula-
tion (V. de Azevedo, City Health Manager, Cape Town; personal 
communication), with a 70% HIV-1/TB coinfection rate [16]. 
The prevalence of diabetes is 13.1% (95% CI, 11.0%–15.1%) 
[17].
Study Design and Sampling
A 3-month cohort study on consecutive patients with res-
piratory symptoms presenting to the clinic from July 2013 to 
August 2015. Patients were eligible if they provided consent, 
were ≥18 years of age, and had received <48 hours of TB che-
motherapy. Those critically ill and in need of emergency clinical 
care were ineligible due to inability to provide informed con-
sent. Based on the 4.5% and 1.2% prevalence of diabetes in TB 
patients and non-TB patients, respectively [13], assuming 80% 
power and 5% significance level, the required sample size was 
798 (n = 399 per group) [18].
Study Procedures
Case Definitions
All participants were tested for TB according to South African 
guidelines [19]. Samples were analyzed in a centralized national 
health laboratory. TB cases had a positive GeneXpert result. 
Non-TB participants were those with a negative GeneXpert re-
sult, who after examination by a physician had resolution of res-
piratory symptoms without TB treatment after 3 months. HIV 
status and antiretroviral therapy (ART) were ascertained from 
participants' medical records. For participants with unknown 
HIV status, voluntary HIV testing was offered, and if found to 
have HIV infection, they were provided counseling and ART 
initiation. All participants were tested for DM using fasting 
plasma glucose (FPG) and glycated hemoglobin (HbA1c). 
DM was defined as self-reported DM, FPG ≥7.0  mmol/L, or 
HbA1c ≥6.5%. Impaired glucose regulation (IGR) was defined 
as FPG 5.5 to <7.0 mmol/L or HbA1c 5.7% to <6.5% [20].
Measurements
After TB diagnosis, sputum microscopy was repeated at 
months 3 and 5 in patients with pulmonary smear-positive 
TB according to South African guidelines [19]. For DM di-
agnosis, venous blood was drawn after an overnight fast for 
FPG. At 3-month follow-up, both DM tests were repeated 
in all participants. All blood samples were processed on the 
day of collection at a centralized national health laboratory 
using standardized operating procedures of the Roche/Hitachi 
Cobas C311 system analyzer assay [21]. Weight, height, and 
waist circumference were measured [22]. The body mass 
index (BMI [kg/m2]) was categorized as follows: under-
weight, <18.5; normal, 18.5–24.9; overweight, 25–29.9; obese, 
≥30) [22]. The cutoff point for high waist circumference was 
≥94 cm (males) and ≥88 cm (females) [22]. Hypertension was 
defined as a single measured blood pressure (BP) of systolic 
BP >140 mm Hg or diastolic BP >90 mm Hg [20], or a preex-
isting diagnosis.
Questionnaire
Socioeconomic, demographic, and chronic medical and medi-
cation history for HIV-1, DM, and hypertension were collected 
using a researcher-administered questionnaire.
Statistical Analysis
Medians and interquartile ranges (IQRs) and proportions sum-
marized continuous and categorical variables. The χ 2 and Fisher 
exact tests assessed associations between categorical variables, 
respectively. The Mann-Whitney test was used to compare 
medians between 2 groups and the Kruskal-Wallis test for >2 
groups. A  multivariable logistic regression model for TB/DM 
association was manually built, using forward selection, con-
trolling for potential confounding variables. To retain statis-
tical power in the regression analysis, multiple imputation 
was used to impute HIV-1 serostatus for 50 participants with 
unknown HIV-1 status. We conducted sensitivity analysis 
comparing complete case and imputed analyses for multivar-
iate analysis results on the association between TB and IGR/
DM (Supplementary Table 1). Statistical significance was set at 
P < .05. All data were analyzed using Stata version 13.0 software 
(StataCorp, College Station, Texas).
Ethical Considerations
This study was approved by the University of Cape Town 
Human Research Ethics Committee (HREC REF: 403/2011).
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RESULTS
Study Sample at Enrollment
Nine hundred eighty-six participants were recruited, and 48 
participants (4.9%) were excluded as TB could not be con-
firmed or excluded. A  further 88 participants did not com-
plete diabetes screening at enrollment. For the analysis, 850 
participants were included: 412 TB cases and 438 non-TB 
participants (Figure 1).
Participant Characteristics at Enrollment
Patient characteristics at enrollment have been previously 
described [12]. The overall median age of participants was 
38 (IQR, 31–47) years, with 53% male. Compared to those 
without TB, TB cases were younger, with a lower prevalence 
of central obesity, a greater proportion of men, and a higher 
proportion of previous incarceration (Table 1). Of the 412 TB 
cases, 9 had rifampicin resistance (2.2%) and did not have di-
abetes. The overall prevalence of HIV-1 infection was 61.1% 
(95% CI, 57.8%–64.4%); 67.2% (95% CI, 62.7%–71.8%) 
among TB cases; and 55.3% (95% CI, 50.1%–59.7%) among 
non-TB cases [12].
Study Sample at Follow-up
Of the 850 patients enrolled, 639 returned for 3-month fol-
low-up with 211 patients lost to follow-up (108 TB,103 
non-TB) (Figure 1). Data comparing participants lost to fol-
low-up to those followed up are presented in Supplementary 
Table 2.
Figure 1. Participant recruitment flow diagram. Abbreviations: DM, diabetes mellitus; TB, tuberculosis.
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Table 1. Characteristics of Participants With and Without Tuberculosis at Enrollment
Characteristic Without TB (n = 438) With TB (n = 412) Total (N = 850) P Value
Age, y
 18–24 16 (3.7) 43 (10.4) 59 (6.9) <.001
 25–34 126 (28.8) 151 (36.7) 277 (32.6)  
 35–44 126 (28.8) 136 (33.0) 262 (30.8)  
 45–54 95 (21.7) 53 (12.9) 148 (17.4)  
 ≥55 75 (17.1) 29 (7.0) 104 (12.2)  
   850  
Age, y, median (IQR) 41 (32–50) 36 (30–43) 38 (31–47) <.001
   850  
Sex    
 Female 224 (51.3) 175 (42.6) 399 (47.0) .011a
   848  
Education level    
 Up to primary 130 (30.4) 129 (32.3) 259 (31.3) .268
 Up to secondary 289 (67.7) 257 (64.3) 456 (66.0)  
 Higher education 8 (1.9) 14 (3.5) 22 (2.7)  
   827  
Marital status    
 Single 276 (64.8) 299 (74.8) 575 (69.6) .002
   826  
Work     
 Unemployed 235 (55.0) 213 (53.5) 448 (54.3) .662
   825  
Household size     
 0–2 individuals 214 (51.7) 230 (59.3) 444 (55.4) .031
 >2individuals 200 (48.3) 158 (40.7) 358 (44.6)  
   802  
Income, Rands, median (IQR) 1295 (600–2970) 1900 (750–3000) 1200 (500–2000) <.001
Binge drinking  698  
 Yes 425 (97.0) 403 (97.3) 828 (97.8) .784
   850  
Current smoker  
 Yes 123 (28.7) 90 (22.5) 213 (25.7) .04
   828  
Prison history     
 Yes 21 (4.9) 42 (10.3) 63 (7.5) .003
   837  
Miner (past or present)  
 Yes 17 (4.0) 7 (1.7) 24 (2.9) .053
   833  
Healthcare worker     
 Yes 8 (1.9) 7 (1.7) 15 (1.8) .889
   838  
TB contact  
 Yes 54 (12.6) 51 (12.6) 105 (12.6) .999
   836  
Previous TB  
 Yes 196 (46.0) 129 (31.9) 325 (39.2) <.001
   830  
Previous DM     
 Yes 19 (4.4) 20 (4.9) 39 (4.7) .717
   838  
HIV-1 status     
 Uninfected 160 (36.5) 121 (29.4) 281 (33.1)
 Infected 242 (55.3) 277 (67.2) 519 (61.1)  
 Unknown 36 (8.2) 14 (3.4) 50 (5.9)  
 Total 438 412 850  
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Glycemic Levels in TB Patients at Enrollment and Follow-up
Among TB patients with newly diagnosed DM, median 
HbA1c decreased at follow-up (5.7% vs 5.4%; P  <  .0001), 
although FPG in this group slightly increased (4.6 vs 
4.7 mmol/L; P < .0064) at follow-up (Table 2). Among those 
with a preexisting diagnosis of DM, glycemic levels were sus-
tained at high levels with no significant changes at follow-up 
(Table 2).
Prevalence of Diabetes and Impaired Glucose Regulation Among Patients 
With TB at Enrollment and Follow-up
The overall (including newly diagnosed DM and preexisting 
DM) prevalence of DM based on either HbA1c or FPG diag-
nostic tests was 11.9% (95% CI, 9.1%–15.4%) at enrollment and 
9.3% (95% CI, 6.4%–13%) at follow-up (P  =  .273). The prev-
alence of IGR was 46.9% (95% CI, 42.15%–51.8%) and 21.5% 
(95% CI, 16.9%–26.3%) at follow-up (P < .001; Table 2). Among 
Table 2. Glycemic Levels Among Participants With Tuberculosis
Glycemic Marker
Enrollment (n = 412) Follow-up (n = 304)
 DM or IGR/Total Prevalence (95% CI)  Median (IQR)   DM or IGR/Total Prevalence (95% CI)  Median (IQR)
IGR       
 HbA1c 147/363 40.7 (36.1–45.6)  6.0 (5.9–6.2) 39/276 12.8 (9.7–17.5)  5.9 (5.8–6.0)
 FPG 40/363 10.9 (8.3–14.4)  5.8 (5.7–6.3) 29/276 10.5 (7.5–14.5)  5.3 (4.8–5.7)
 HbA1c or FPG 177/363 48 (42.2–51.8)  … 62/276 21.8 (16.9–26.3)  …
Newly diagnosed DM and preexisting DMa 
 HbA1c 42/410 10.2 (7.6–13.6) 7.6 (6.6–11.7) 16/296 5.4 (3.3–8.6) 10.3 (7.3–11.3)
 FPG 18/410 4.4 (.3–6.9) 8.9 (7.8–12.0) 13/296 4.4 (2.6–7.5) 10.6 (7.2–15.4)
 HbA1c or FPG 48/410 11.9 (9.10–15.4) … 22/296 9.3 (6.4–13.0) …
Newly diagnosed DM only     
 HbA1c 25/390 6.4 (4.2–9.2) 6.7 (6.5–7) 6/284 2.1 (1.0–4.7) 6.6 (6.6–10.8)
 FPG 9/390 2.3 (1.2–4.4) 8.7 (8.1–8.9) 4/284 1.4 (.5–3.7) 10.3 (7.1–14.5)
 DM defined by HbA1c or FPG 28/390 7.1 (5.1–10.4)  … 9/284 2.9 (1.4–5.7)  …
Preexisting DM only       
 HbA1c 18/20 89.5 (62.9–97.7) 11.2 (7.9–12.9) 10/14 71.4 (39.9–90.4) 9.3 (5.7–11.2)
 FPG 9/20 45 (25.0–70.8) 6.9 (4.8–10.1) 9/14 64.3 (39.9–90.4) 8.7 (6.4–15.4)
 HbA1c or FPG 20/20 100.00  … 14/14 100.00  …
Abbreviations: CI, confidence interval; DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IGR, impaired glucose regulation; IQR, interquartile range; TB, 
tuberculosis. 
aDifferences in denominator (n = 2 at enrollment and n = 8 at follow-up) due to exclusion of participants with missing DM diagnostic tests for either test.
Characteristic Without TB (n = 438) With TB (n = 412) Total (N = 850) P Value
   850  
ART status, among those with HIV-1 infection   
 Yes 166 (68.6) 89 (31.9) 255 (48.9) <.001
   521  
Hypertension  
 Yes 154 (35.2) 75 (18.1) 229 (26.9) <.001
   850  
BMI     
 <18 kg/m2 (underweight) 27 (6.6) 41 (10.3) 68 (8.4) <.001
 18–25 kg/m2 (normal) 224 (54.4) 277 (69.6) 501 (61.9)  
 26–30 kg/m2 (overweight) 69 (16.8) 59 (14.8) 128 (15.8)  
 >30 kg/m2 (obese) 92 (22.3) 21 (5.3) 113 (14.0)  
   810  
Waist circumference     
 Raised (>94 cm males; >88 cm females) 144 (28.9) 53 (14.3) 167 (21.8) <.001
   765  
Data are presented as no. (%) unless otherwise indicated. Number of participants is shown at the end of each category. Values in bold indicate statistical significance.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; TB, tuberculosis.
Table 1. Continued
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those with preexisting DM, glycemic levels were high (Table 2) 
beyond the cutoff for DM diagnosis at both enrollment and fol-
low-up (Table 2).
Glycemic Profile Among TB Patients
At enrollment, using both combined tests, 58.9% (n = 243) of 
TB patients were hyperglycemic (DM and IGR). This preva-
lence decreased to 30.8% (n = 94) at follow-up (Figure 2); 2.6% 
(n = 10) with DM at enrollment reverted to normal at follow-up; 
and 22.5% (n = 105) of patients with IGR reverted to normal 
at follow-up (Figure 2). With respect to diagnostic test, hyper-
glycemia detected by HbA1c was 51.2% (n = 186) enrollment 
and 18.5% (n = 65) at follow-up; and hyperglycemia detected 
by FPG was 15.4% (n = 38) at enrollment and 14.9% (n = 37) 
at follow-up.
Association Between Hyperglycemia (DM and IGR) and TB at Enrollment 
and Follow-up
Irrespective of HIV-1 status, the overall TB/DM association was 
positive and significant at both enrollment (OR, 2.4 [95% CI, 
1.3–4.3]) and at follow-up (OR, 3.3 [95% CI, 1.5–7.3]) but only 
when DM was defined by a positive result for either of the diag-
nostic tests or a previous DM history (Table 3). This significant 
association was not observed at either time point when DM di-
agnostic tests were used in isolation (Table 3).
The overall association between TB and IGR (by FPG or 
HbA1c) was positive at enrollment (OR, 2.3 [95% CI, 1.6–3.3]; 
Table 3) but not at follow-up (OR, 0.8 [95% CI, .5–1.4]). On 
further analysis by DM diagnostic test, the overall TB/IGR 
association at enrollment was significant when using the HbA1c 
test (OR, 1.6 [95% CI, 1.1–2.3]) but not by FPG (OR, 0.9 [95% 
CI, .5–1.5]) (Table 3).
Comparison of the Association Between TB/Newly Diagnosed DM and TB/
Preexisting DM
At enrollment, 4.5% (95% CI, 2.8%–6.8%; n = 20) of patients 
had preexisting DM. All these patients had poorly controlled 
DM as evidenced by high glycemic levels at enrollment and 
follow-up (Table 2). On restricting analysis to patients with 
newly diagnosed DM, the TB/DM association was significant 
at enrollment (OR, 2.12 [95% CI, 1.0–4.7]) but not at follow-up 
(Table 3). By contrast, the association between TB and preex-
isting DM was significant at both enrollment (OR, 3.7 [95% CI, 
1.5–9.1]) and follow-up (OR, 4.0 [95% CI, 1.6–10.1]) (Table 3).
DISCUSSION
We previously reported the prevalence of DM in patients with 
newly diagnosed TB and the cross-sectional TB/DM associa-
tion at enrollment [12]. In this study, we investigated whether 
hyperglycemia identified in the patients with newly diagnosed 
TB at enrollment persisted after 3 months of TB treatment. We 
also assessed association between TB and hyperglycemia at both 
time points. This is the first study in South Africa, a setting of 
high TB and DM burden, to document transient hyperglycemia 
in TB patients with preexisting DM and newly diagnosed DM. 
Overall, we report significant association between TB and DM 
at both enrollment and follow-up and significant association 
Figure 2. Changes in the prevalence (%) of hyperglycemia (IGR and DM) among patients with tuberculosis (TB) at enrollment (when TB diagnosed) and follow-up (3 months 
later). Abbreviations: DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IGR, impaired glucose regulation.
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Table 3. Association Between Tuberculosis and Diabetes Mellitus or Impaired Glucose Regulation at Enrollment and 3-Month Follow-up
Characteristic
Enrollment Follow-up 
Overall  
(N = 850)
Participants  
With HIV  
(n = 541)
Partcipants  
Without HIV  
(n = 309)
Overall  
(N = 639)
Participants  
With HIV  
(n = 399)
Participants 
Without HIV 
(n = 240)
IGR       
 No IGR 1.0 1.0 1.0 1.0 1.0 1.0
 IGR by HbA1c 1.6 (1.1–2.3) 1.5 (1.0–2.3) 2.2 (1.2–4.1) 0.6 (.4–1.1) 0.6 (.3–1.2) 0.8 (.3–2.0)
 IGR by FPG 0.9 (.5–1.5) 1.2 (.6–2.2) 0.4 (.1–1.2) 1.2 (.6–2.3) 0.8 (.3–2.2) 1.6 (.6–4.2)
 IGR by combined test (HbA1c 
or FPG)
2.3 (1.6–3.3) 2.4 (1.51–3.8) 2.3 (1.1–4.7) 0.84 (.53–1.36) 0.77 (.41–1.16) 1.10 (.47–2.57)
Combining preexisting DM and newly diagnosed DM     
 No DM 1.0 1.0 1.0 1.0 1.0 1.0
 DM by HbA1c 2.4 (1.2–4.6) 2.4 (1.0–5.9) 2.2 (.7–6.3) 2.1 (.8–5.3) 2.5 (.5–11.8) 1.8 (.5–6.7)
 DM by FPG 2.3 (1.0–5.9) 2.9 (.7–12.2) 1.9 (.7–6.4) 2.8 (.9–8.4) 9.8 (.9–106.6) 1.6 (.4–6.5)
 DM by combined test (HbA1c 
or FPG)
2.8 (1.5–5.3) 2.4 (1.0–5.3) 3.5 (1.2–9.8) 3.3 (1.5–7.3) 3.8 (1.2–12.3) 3.5 (1.1–11.0)
Newly diagnosed DM only      
 No DM 1.0 1.0 1.0 1.0 1.0 1.0
 DM by HbA1c 1.6 (.7–3.6) 1.7 (1.0–2.9) 1.0 (.1–7.6) 1.5 (.3–7.0) 1.3 (.2–8.1) 2.4 (.1–49.1)
 DM by FPG 1.7 (.3–8.8) 9.2 (.9–97.0) 2.2 (1.0–4.7) 3.0 (.2–40.5) a 2.0 (.6–7.2)
 DM by combined test (HbA1c 
or FPG)
2.2 (1.0–4.7) 1.6 (.7–4.0) 3.6 (.7–19.5) 2.0 (.6–7.2) 1.6 (.3–7.3) 4.5 (.3–59.9)
Preexisting DM only      
 No DM 1.0 1.0 1.0 1.0 1.0 1.0
 DM 3.7 (1.5–9.1) 6.3 (1.3–30.8) 3.1 (.9–10.1) 4.0 (1.6–10.1) 9.3 (1.7–49.0) 3.0 (.9–10.1)
Data are presented as odds ratio (95% confidence interval). Bold text represents significant associations. Reference group for the associations: patients with no DM or IGR. All odds ratios 
were adjusted for sex, age, household size, income, hypertension (baseline), previous miner, previous prisoner, marital status, work status, and HIV-1 status.
Abbreviations: DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HIV, human immunodeficiency virus; IGR, impaired glucose regulation. 
aInsufficient data to perform test-specific analysis. 
between TB and IGR at enrollment but not follow-up. However, 
when these results were further analyzed by DM category 
(newly diagnosed vs preexisting) and by HIV status within 
these categories, differing patterns emerged. Given the socioec-
onomic conditions of our study setting, the patients with newly 
diagnosed DM in our study may represent the proportion of 
undiagnosed DM due to factors associated with limited access 
to DM screening and having health facilities overwhelmed by 
TB and HIV [17].
Newly Diagnosed DM
Hyperglycemia, transient in the majority of participants with 
newly diagnosed DM and IGR, was predominantly accounted 
for by the latter at enrollment, and normalized at follow-up. 
Similar to our findings, other studies have shown frequent hy-
perglycemia in patients with TB at initiation of TB treatment, 
followed by normalization during treatment [23]. This may be 
due to inflammation in response to active TB [25–27], driven 
by complex interactions between hormones and cytokines [24].
Consistent with the literature, the association between DM/
IGR and TB in newly diagnosed DM participants was only sig-
nificant at enrollment but not at follow-up. With respect to the 
different diagnostic tests separately, none of the associations 
were significant.
Preexisting DM
Patients with preexisting DM had poorly controlled disease at 
both diagnosis of TB and 3 months later, as reflected by both 
FPG and HbA1c at these timepoints. Unlike newly diagnosed 
DM participants, the significant TB/DM association at enroll-
ment (OR, 3.7 [95% CI, 1.5–9.1]) in this group, which persisted 
at follow-up (OR, 4.0 [95% CI, 1.6–10.1]), reflects poor glycemic 
control between the study timepoints. Hyperglycemia may have 
been exacerbated by acute TB. The persistence of raised gly-
cemic levels reflects inadequate management of these patients, 
possibly due to poor follow-up, and highlights the complexity of 
clinical care in this subgroup.
A Korean retrospective study showed that TB is usually diag-
nosed 1 year following the diagnosis of DM [27]. Therefore, the 
observed relative odds of preexisting DM among patients with 
TB compared to those without TB in this study (OR, 2.8 [95% CI, 
1.5–5.3]) may approximate the relative risk to develop TB among 
patients with diabetes. Although the temporal relationship be-
tween TB and DM remains contentious, irrespective of the causal 
direction, comorbidity of TB and DM increases the risk of adverse 
TB treatment outcomes including treatment failure, mortality, and 
drug resistance [3, 5, 13]. The observed poorly managed DM in 
these individuals with TB also highlights the increased risk of ad-
verse TB treatment outcomes among these patients.
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When stratified by HIV-1 status, the TB/DM association (when 
DM is defined by the different diagnostic tests separately) was 
not significant at either time point. Interaction between HIV, 
TB and DM is still not well understood and different studies 
report varying results.
It is complicated to interpret the interplay between TB, HIV, 
and DM as a wide range of factors may influence what is ob-
served. This includes the effect of ART, HIV-1 infection as an 
independent risk factor for both DM and TB, or the choice of 
diagnostic test. Cotrimoxazole, administered to people living 
with HIV-1, can lead to hypoglycemia [28]. Conversely, ART, 
particularly regimens containing protease inhibitors, increases 
insulin resistance, thus increasing the risk of diabetes [29].
Other studies suggest that HbA1c may underestimate the pres-
ence of hyperglycemia in people living with HIV-1 and that this 
may be due to nucleoside reverse transcriptase inhibitor use [30, 
31]. In our study, HbA1c detected a higher prevalence of hyper-
glycemia. In a 2015 review by English et al, it was suggested that 
an HbA1c test is likely to be affected by iron deficiency anemia 
and may result in spurious increases of HbA1c level [32]. On the 
other hand, non–iron deficiency anemia may lead to a reduction 
in HbA1c levels [32, 33]. A recent study observed lower HbA1c 
mean levels in severely anemic patients; however, due to a limited 
sample, no further analysis was performed to explore this relation-
ship [34]. The effect of anemia on the direction of the association 
is therefore unclear.
We explored the potential effect of unmeasured confounding 
on our results by performing sensitivity analysis (Supplementary 
Table 3) [35]. This showed that in IGR and newly diagnosed DM, 
the association with TB was rendered nonsignificant at baseline 
and follow-up. As such we note that weaker residual confounding 
may explain away our observed estimates. However, the associa-
tion between TB and preexisting DM was significant both at en-
rollment and follow-up with ORs ranging between 3.7 and 9.3. 
To explain away these associations, an unmeasured confounder 
would need to be associated with both TB and preexisting DM 
with risk ratios ranging between 2.9 and 6.9, but weaker con-
founding would not.
There were strengths and limitations to this study. A limited 
number of studies have evaluated hyperglycemia in individuals 
with TB, particularly in Africa where there is a high prevalence 
of comorbidity with other diseases such as HIV-1. TB cases 
were diagnosed according to South African guidelines [19], 
with the Gene Xpert analyzed in a centralized national health 
laboratory. For enrollment and follow-up, DM measurements 
were performed using 2 recommended tests. We relied on med-
ical records to document ART use, as such we could not reliably 
ascertain duration of ART use in our multivariate analysis.
Our study follow-up time was limited to 3 months and we 
were not able to analyze the effect of hyperglycemia on TB 
outcomes. Because critically ill patients were excluded in 
the study, it may have biased the study population to appear 
healthier.
The proportion of participants lost to follow-up in this 
study, and to the health system, was relatively high (n = 212 
[24.9%]) (Supplementary Table 2). Those followed up were 
older, mostly unemployed, and likely to have known DM and 
hypertension. Our results at follow-up may thus be slightly bi-
ased as they represent an older population prone to chronic 
conditions. Reasons for loss to follow-up include migration 
to other parts of the country and transfer to other health fa-
cilities in the province. To reduce bias and loss of statistical 
power, we imputed HIV status for patients with unknown 
HIV status. Therefore, loss to follow-up is less likely to have 
biased the associations observed in the study. The loss to fol-
low-up observed in this study reflects how patients are lost in 
healthcare systems in this setting. This therefore highlights the 
importance of improving retention of patients in care for op-
timal management of all chronic diseases.
CONCLUSIONS
This is the first study in the South African context of high TB/HIV 
and rapidly increasing DM burdens to describe changes in glu-
cose levels among patients with TB during treatment. This study 
showed that hyperglycemia was common in TB patients with DM. 
This confirms the need for confirmation DM tests in TB patients 
during and/or after the course of TB treatment. The association 
between DM and TB persisted at follow-up in participants with 
preexisting DM, particularly those infected with HIV-1. This high-
lights an important need for improved co-management of TB, DM, 
and HIV to limit the risks of adverse outcomes.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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